Last €49.59 EUR
Change Today -0.057 / -0.11%
Volume 175.0
DSM2 On Other Exchanges
EN Amsterdam
As of 11:25 AM 09/15/14 All times are local (Market data is delayed by at least 15 minutes).

koninklijke dsm nv (DSM2) Snapshot

Previous Close
Day High
Day Low
52 Week High
11/19/13 - €60.08
52 Week Low
02/27/14 - €45.67
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for KONINKLIJKE DSM NV (DSM2)

Related News

No related news articles were found.

koninklijke dsm nv (DSM2) Related Businessweek News

View More BusinessWeek News

koninklijke dsm nv (DSM2) Details

Koninklijke DSM N.V. operates as a life sciences and materials sciences company worldwide. The company operates in five segments: Nutrition, Pharma, Performance Materials, Polymer Intermediates, and Innovation Center. It manufactures food enzymes, cultures, savory ingredients, and other specialties, as well as nutritional products, such as vitamins, carotenoids, eubiotics, feed enzymes, premixes, nutritional lipids, and cultures for the food and beverage, feed, personal care, dietary supplements, and pharmaceutical industries. The company also provides custom manufacturing and development services to the pharmaceutical, biopharmaceutical, and agrochemical industries; and beta-lactam active pharmaceutical ingredients, such as semi-synthetic penicillins and semi-synthetic cephalosporins, as well as nystatin. In addition, it offers engineering thermoplastic solutions; Dyneema, a strong fiber; and resins solutions for paints and coatings, composite materials, and optical fiber coatings. Further, the company produces caprolactam and acrylonitrile that are raw materials for synthetic fibers and plastics; and other products, including ammonium sulfate, sodium cyanide, cyclohexanone, and diaminobutane. Additionally, it develops materials-based solutions comprising coatings, drug delivery platforms, and a range of biomedical materials for medical device and biopharmaceutical industries; creates solutions for bioconversion of feedstocks for the production of bio-energy, such as cellulosic biofuels, as well as bio-based chemicals and materials; and provides smart coatings and surface technologies to the solar industry. The company was founded in 1902 and is headquartered in Heerlen, the Netherlands.

21,453 Employees
Last Reported Date: 08/5/14
Founded in 1902

koninklijke dsm nv (DSM2) Top Compensated Officers

Chairman of Managing Board, Chief Executive O...
Total Annual Compensation: €1.4M
Chief Financial Officer and Member of the Man...
Total Annual Compensation: €902.0K
Member of The Managing Board
Total Annual Compensation: €954.0K
Member of Managing Board
Total Annual Compensation: €887.0K
Member of The Managing Board
Total Annual Compensation: €268.0K
Compensation as of Fiscal Year 2013.

koninklijke dsm nv (DSM2) Key Developments

DSM Expands Dyneema Purity Fiber Portfolio with the Release of Dyneema Purity Radiopaque Fiber

DSM announced the launch of its Dyneema Purity Radiopaque fiber, the only radiopaque ultra-high-molecular-weight-polyethylene medical fiber in the world. The fiber is the newest addition to DSM's medical Dyneema Purity fiber portfolio. Dyneema Purity Radiopaque fiber is designed to support the development of medical devices for use in orthopedic trauma. The fiber contains a radiopacifier, which makes it the only UHMWPE fiber currently available that is visible in x-ray images. This feature helps surgeons with medical device and implant visualization both during and after surgical interventions. The fiber will initially be used as a replacement for metal surgical cables that are used in procedures to treat bone fractures. The fiber is 15 times stronger than steel but maintains high pliability and increased flexibility, which may help lower the risk of bone damage. Steel does not conform well to the natural contours of the human body. A small contact point between the bone and metal wire leads to high levels of pressure in a concentrated area during surgery. On the other hand, UHMWPE fibers conform directly to complex bone anatomy, which increases surface contact and spreads force more evenly, reducing the risk of the cable cutting into the bone. The fiber is biocompatible and chemically inert, which can help reduce tissue inflammation, irritation and complications associated with metal allergies. All of these factors can increase patient comfort and promote shorter healing times. UHMWPE fiber has additional advantages for cable construction. If a steel cable is wrapped around portions of a bone that require repairs, both ends of the cables must be guided through a tensioning device. Once fixation is complete, no incremental adjustments are possible and a re-adjustment can only be accomplished by cutting the cable and starting all over again. In contrast, a cable construction made from UHMWPE fiber promotes more flexibility and allows for re-tensioning after primary fixation without the need to start from scratch.

Koninklijke DSM N.V. Launches Cellular Therapy Development Services

Koninklijke DSM N.V. launched its cellular therapy development services. Cellular therapies use a patient's own cells to improve healing of an injury or disease. DSM develops products that are distributed by major biotechnology and medical device companies into the hands of qualified physicians, who are ultimately responsible for patient care. DSM offers a complete package of design, development and manufacturing services to create cellular therapy products that are clinically valuable and commercially viable. The first product, developed by DSM and launched by DePuy Synthes Mitek Sports Medicine, concentrates platelets from whole blood in only two and a half minutes. The DePuy Synthes Mitek Sports Medicine PEAK Platelet Rich Plasma System yields a higher concentration of undamaged platelets and a more consistent output than existing devices on the market. Further, the device weighs only four pounds, making it easy to store in surgical specialty rooms as well as transport through a doctor's office or hospital.

Koninklijke DSM N.V., Board Meeting, Jul 28, 2014

Koninklijke DSM N.V., Board Meeting, Jul 28, 2014. Agenda: To approve portfolio manager changes.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DSM2:GR €49.59 EUR -0.057

DSM2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Grupo Bimbo SAB de CV $39.71 MXN -0.41
Huntsman Corp $28.17 USD -0.32
LANXESS AG €47.53 EUR -0.22
Merck KGaA €67.49 EUR +0.19
Solvay SA €118.50 EUR +0.40
View Industry Companies

Industry Analysis


Industry Average

Valuation DSM2 Industry Range
Price/Earnings 54.8x
Price/Sales 0.9x
Price/Book 1.4x
Price/Cash Flow 39.6x
TEV/Sales 0.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KONINKLIJKE DSM NV, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at